Discovery Labs Shares Fall on FDA Delay of Surfaxin
Shares in Discovery Labs spiraled downward 52 percent Monday on news that the FDA has again delayed a decision on the company’s application to market Surfaxin for the prevention of respiratory distress syndrome in premature infants. For the fourth time, the agency has issued a complete [...]